Free shipping on all orders over $ 500

Revumenib (SNDX-5613)

Cat. No. M13387
Revumenib (SNDX-5613) Structure
Synonym:

SNDX5613

Size Price Availability Quantity
5mg USD 190  USD190 In stock
10mg USD 330  USD330 In stock
25mg USD 600  USD600 In stock
50mg USD 980  USD980 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Revumenib (SNDX-5613) is an effective and selective Menin-MLL binding inhibitor with Ki of 0.15 nM. Sndx-5613 can be used to study MLL gene rearrangement in acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Chemical Information
Molecular Weight 630.82
Formula C32H47FN6O4S
CAS Number 2169919-21-3
Solubility (25°C) DMSO ≥ 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Huanrong Bai, et al. Expert Opin Ther Pat. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021)

[2] Warren Fiskus, et al. Blood Cancer J. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Related Epigenetic Reader Domain Products
Phoenixin-20

Phoenixin-20 (PNX-20) is a bioactive peptide with hormone-like actions in vertebrates, and can stimulates hypothalamo-pituitary-gonadal hormones and regulate reproductive processes in mammals.

Menin-MLL inhibitor 31

Menin-MLL inhibitor 31 is a potent inhibitor of the menin MLL interaction with an IC50 value of 4.6 nM.

OPN-2853

OPN-2853 is a bromodomain protein-4 (BRD4) inhibitor that can be used in studies related to hematologic and lymphatic disorders.

HDAC/JAK/BRD4-IN-1

HDAC/JAK/BRD4-IN-1 is a potent HDAC/JAK/BRD4 triple inhibitor.

VYN-201

VYN-201 is a novel pan-BET inhibitor for studies related to idiopathic pulmonary fibrosis.

  Catalog
Abmole Inhibitor Catalog




Keywords: Revumenib (SNDX-5613), SNDX5613 supplier, Epigenetic Reader Domain, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.